Zydus receives final approval from USFDA for Roflumilast Tablets, 250 mcg

Roflumilast reduces inflammation in the lungs that leads to chronic obstructive pulmonary disease (COPD)

Multiple sclerosis market to generate sales of $29.8 billion by 2030, forecasts GlobalData

Several late-stage pipeline products have the potential to address some of these unmet needs

Zydus receives final approval from the USFDA for Estradiol Transdermal System

Estradiol Transdermal System USP, 0.014 mg/day (weekly) had annual sales of USD 1.9 mn in the United States

Zydus receives final approval from the USFDA for Isoproterenol Hydrochloride Injection

Isoproterenol hydrochloride injection is indicated to improve hemodynamic status in patients in distributive shock and shock due to reduced cardiac output

Merck acquires Prometheus Biosciences for US$10.8 billion to strengthen immunology pipeline

Prometheus Biosciences’ comprehensive data set enables target discovery and precision medicine approach in inflammation and immunology

Max Healthcare Institute completes acquisition of further stake in Eqova Healthcare

The company had acquired 26,000 equity shares having face value of Rs. 10 each fully paid up of Eqova

AI-backed innovations to drive Australia ultrasound systems market, says GlobalData

Zydus receives final approval from USFDA for Tavaborole Topical Solution

Tavaborole Topical Solution, 5% had annual sales of US $3.1 million in the United States

Zydus receives final approval from the USFDA for Azithromycin Tablets

Azithromycin Tablets USP, 500 mg had annual sales of US $20 million in the United States

Mandaviya visits RML, reviews mock drill for ensuring COVID readiness

Urges everyone to follow COVID Appropriate Behaviour and curb any misinformation